Theravance Biopharma Inc expected to post a loss of 33  cents a share - Earnings Preview

Theravance Biopharma

22/02/2022 03:07

* Theravance Biopharma Inc  TBPH.OQ   TBPH.O  is expected
to show
a fall in quarterly revenue when it reports  results on February
23. 
    * The George Town Grand Cayman-based  company is expected to
report  a 28.0% decrease in revenue to $13.482 million from
$18.73 million a year ago, according to the mean estimate from 7
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Theravance
Biopharma Inc
is for a loss of 33 cents per share. For the same quarter last
year, the company reported a loss of 92 cents per share.
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 4
"hold" and 2 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Theravance
Biopharma Inc is $10​, about 3.9% above​ its last closing price
of $9.61. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.56       -0.56      -0.48     Beat    14.1
 Jun. 30 2021  -1.02       -1.00      -0.80     Beat    19.9
 Mar. 31 2021  -1.05       -1.05      -1.24     Missed  -18.3​
 Dec. 31 2020  -1.02       -1.02      -0.92     Beat    9.4
 ​​Sep.        -0.99       -1.01      -1.16     Missed  -14.5
 30 2020                                                
 Jun. 30 2020  -0.98       -0.98      -1.00     Missed  -2.4​
 Mar. 31 2020  -1.09       -1.07      -1.40     Missed  -30.2
 Dec. 31 2019  -1.13       -1.13      -1.17     Missed  -3.4
 This summary was machine generated February 22 at 03:07 GMT. 
All figures in US dollars  unless otherwise stated